Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206

Journal of Clinical Oncology

Volumn 23, Issue 35, 2005, Pages 8968-8977

  Ribas, Antoni ^a   Camacho, Luis H ^a   Lopez Berestein, Gabriel ^a   Pavlov, Dmitri ^a   Bulanhagui, Cecile A ^a   Millham, Robert ^a   Comin Anduix, Begoña ^a   Reuben, James M ^a   Seja, Elisabeth ^a   Parker, Charla A ^a   Sharma, Amarnath ^a   Glaspy, John A ^a   Gomez Navarro, Jesus ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CP 675206; CYTOKINE; DENDRITIC CELL VACCINE; HISTAMINE; INTERLEUKIN 2; IPILIMUMAB; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; CANCER ANTIBODY; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MART1 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHMA; AUTOIMMUNITY; CANCER GROWTH; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG FORMULATION; DYSPEPSIA; FATIGUE; FEMALE; FEVER; HERPES; HUMAN; HYPERTHYROIDISM; HYPOKALEMIA; HYPOPITUITARISM; IMMUNE RESPONSE; INSOMNIA; MALE; MELANOMA; NAUSEA; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; SIDE EFFECT; THERAPY EFFECT; TINNITUS; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VITILIGO; WEIGHT REDUCTION; AUTOIMMUNE DISEASE; COLON TUMOR; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; NEOPLASM; PATHOLOGY; REGRESSION ANALYSIS; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; AUTOIMMUNE DISEASES; CANCER VACCINES; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; REGRESSION ANALYSIS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 32644467549     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.109     Document Type: Article

References (32)

1. Shankaran V, Ikeda H, Bruce AT, et al: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107-1111, 2001
2. Dunn GP, Bruce AT, Ikeda H, et al: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998, 2002
3. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-1736, 1996
4. Chambers CA, Kuhns MS, Egen JG, et al: CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565-594, 2001
5. Wang XB, Giscombe R, Van Z, et al: Expression of CTLA-4 by human monocytes. Scand J Immunol 55:53-60, 2002
6. Paust S, Lu L, McCarty N, et al: Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci USA 101:10398-10403, 2004
7. Grohmann U, Orabona C, Fallarino F, et al: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3:1097-1101, 2002
8. Munn DH, Sharma MD, Hou D, et al: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280-290, 2004
9. Mellor AL, Chandler P, Baban B, et al: Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 16:1391-1401, 2004
10. Waterhouse P, Penninger JM, Timms E, et al: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270:985-988, 1995
11. Tivol EA, Bornello F, Schweitzer AN, et al: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547, 1995
12. Hansen D, Canniff P, Primiano M, et al: Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Proc Am Assoc Cancer Res, 2004 (abstr 3802)
13. Keler T, Halk E, Vitale L, et al: Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. I Immunol 171:6251-6259, 2003
14. Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712-4717, 2003
15. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003
16. Sanderson K, Scotland R, Lee P, et al: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23:741-750, 2005
17. Chatenoud L, Ferran C, Legendre C, et al: In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49:697-702, 1990
18. Wing MG, Moreau T, Greenwood J, et al: Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98:2819-2826, 1996
19. Byrd JC, Waselenko JK, Maneatis TJ, et al: Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791-795, 1999
20. Criteria NCT: The revised Common Toxicity Criteria version 2.0. http://ctep.info.nih.gov/reporting/ctc.html
21. Lee SY, Lee YH, Shin C, et al: Association of asthma severity and bronchial hyperresponsiveness with a polymorphism in the cytotoxic T-lymphocyte antigen-4 gene. Chest 122:171-176, 2002
22. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
23. MathSoft: S-PLUS 2000 Guide to Statistics, Vol 1. Data Analysis Products Division, Seattle, WA, 1999, p 301
24. Ribas A, Glaspy JA, Lee Y, et al: Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27:354-367, 2004
25. Morell A, Terry WD, Waldmann TA: Metabolic properties of IgG subclasses in man. J Clin Invest 49:673-680, 1970
26. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001
27. Chang E, Rosenberg SA: Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy. J Immunother 24:88-90, 2001
28. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-66
29. Eigentler TK, Caroli UM, Radny P, et al: Palliative therapy of disseminated malignant melanoma: A systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-759, 2003
30. Falkson CI, Ibrahim J, Kirkwood JM, et al: Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 16:1743-1751, 1998
31. McCoy KD, Hermans IF, Fraser JH, et al: Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help. J Exp Med 189:1157-1162, 1999
32. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823-832, 2001